[{"id":"62f5edd5-c957-457e-9d82-168589f4f65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05654532","created_at":"2022-12-16T14:58:24.247Z","updated_at":"2024-07-02T16:35:20.366Z","phase":"Phase 1","brief_title":"Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05654532","lead_sponsor":"Accutar Biotechnology Inc","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AC699"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-07"}]